Squarepoint’s ClearPoint Neuro CLPT Stock Holding History

Squarepoint’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38,110	Closed	-$453K	–	4556
2025 Q1	$453K	Buy	+38,110	New	+$592K	﹤0.01%	3397
2024 Q4	–	Sell	-37,201	Closed	-$417K	–	5062
2024 Q3	$417K	Sell	37,201 -64,572	-63%	-$618K	﹤0.01%	3234
2024 Q2	$549K	Buy	+101,773	New	+$589K	﹤0.01%	3010
2022 Q1	–	Sell	-17,029	Closed	-$191K	–	2903
2021 Q4	$191K	Buy	+17,029	New	+$255K	﹤0.01%	2722

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Squarepoint's CLPT Position: Q2 2025 in Review

Squarepoint sold out of ClearPoint Neuro (CLPT) in Q2 2025, closing a stake of 38,110 shares — an estimated $453K sold.

Squarepoint first reported a position in CLPT in Q4 2021 and held it in 4 quarters. The position peaked at $549K in Q2 2024. 96 funds tracked by Wall St. Rank hold CLPT as of Q2 2025.

Squarepoint reported no remaining ClearPoint Neuro position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 38,110 ClearPoint Neuro shares in Q2 2025, an estimated $453K.
Squarepoint first reported a position in ClearPoint Neuro in Q4 2021 and held it in 4 quarters.
Squarepoint's ClearPoint Neuro position peaked at $549K in Q2 2024.
96 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.